Retinoblastoma Solutions is certified for molecular diagnostic testing by the College of American Pathologists
and registered under CLIA-88, as required for testing US families.
Retinoblastoma Solutions is a member of the European Molecular Quality Network and a
participant in every External Quality Assessment Scheme the EMQN has run for Retinoblastoma.
Dr. Dietmar Lohmann and Dr. Brenda Gallie, co-founder and chief medical officer of Retinoblastoma Solutions, wrote the EMQN
"Best Practice Guideline" for retinoblastoma and the GeneReviews entry for retinoblastoma.
